Highlights:

RMD declares an unfranked dividend of USD 0.06 per CDI, payable in AUD equivalent

ResMed confirms dividend subject to 30% US withholding tax for Australian CDI holders

The Company will provide AUD conversion rate for dividend payment on 15 August 2025

ResMed Inc (ASX:RMD), a global developer of cloud-connected medical devices and digital health solutions for sleep apnea and other chronic respiratory conditions, has declared a quarterly unfranked dividend of USD 0.06 per Chess Depositary Instrument (CDI) for holders listed on the Australian Securities Exchange (ASX). The announcement was lodged with the ASX on 1 August 2025. This dividend distribution is denominated in US dollars, with the AUD equivalent to be calculated based on the prevailing exchange rate on the record date, which will be announced on or before 15 August 2025. The dividend reflects the 10:1 ratio between ASX-listed CDIs and the company’s common stock listed on the New York Stock Exchange (NYSE). Holders of CDIs are entitled to receive the equivalent of USD 0.60 per share of US common stock, proportional to their holdings.

According to the announcement, 100% of the dividend is unfranked, meaning that Australian shareholders will not receive any franking credits for tax purposes. Additionally, a 30% US withholding tax will be applied to the distribution, in accordance with United States tax regulations for foreign investors. This tax rate is consistent with the withholding obligations applied to dividends paid to non-resident holders of US-sourced income. ResMed has not indicated any additional tax component information apart from the franking status and withholding tax rate. Furthermore, the company does not currently operate a dividend reinvestment plan or any currency-related arrangements that would allow shareholders to choose a preferred payment currency.

The dividend amount of USD 0.06 per CDI will be paid out in Australian dollars, with the exact payment amount per CDI depending on the AUD/USD exchange rate on the record date. The final AUD amount will be released on 15 August 2025. This aligns with ResMed's established practice of announcing US-dollar dividends to ASX CDI holders and then converting them to AUD for payment purposes. This latest dividend applies to holders of the company’s CDI 10:1 FOREIGN EXEMPT NYSE securities trading on the ASX under ticker code RMD. As an exempt foreign entity on the ASX, ResMed complies with applicable Australian disclosure requirements while being primarily regulated by US securities laws due to its NYSE listing.

ResMed is incorporated in the United States and operates globally, delivering medical technologies focused on sleep and respiratory care. Its product portfolio includes CPAP devices, ventilators, software platforms, and related accessories, used by patients across more than 140 countries. The company reports financial results and dividend declarations in USD, with conversions provided for international shareholders based on respective listing jurisdictions. No additional approvals or external conditions were indicated as prerequisites for this dividend distribution as of the announcement date.

ResMed will continue to communicate with ASX-listed shareholders and update the market once the Australian dollar equivalent is finalised and available for distribution.

RMD shares were trading 1.98% lower at AUD 271.94 per share as of 1 August 2025.